These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 8663015)

  • 21. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
    J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist.
    Morrow JD; Minton TA; Roberts LJ
    Prostaglandins; 1992 Aug; 44(2):155-63. PubMed ID: 1438879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic activity of the non-prostanoid thromboxane A2 receptor antagonist, daltroban (BM 13,505), in human platelets in vitro and in the rat vasculature in vivo.
    Bertolino F; Valentin JP; Maffre M; Grelac F; Bessac AM; Maclouf J; Delhon A; Lévy-Toledano S; Patoiseau JF; Colpaert FC
    Br J Pharmacol; 1995 May; 115(1):210-6. PubMed ID: 7647979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha.
    Kunapuli P; Lawson JA; Rokach J; FitzGerald GA
    J Biol Chem; 1997 Oct; 272(43):27147-54. PubMed ID: 9341156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoconstrictor effects of iso-prostaglandin F2alpha type-III (8-iso-prostaglandin F2alpha) on human saphenous veins.
    Gardan B; Cracowski JL; Sessa C; Hunt M; Stanke-Labesque F; Devillier P; Bessard G
    J Cardiovasc Pharmacol; 2000 May; 35(5):729-34. PubMed ID: 10813374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
    Okwu AK; Ullian ME; Halushka PV
    J Pharmacol Exp Ther; 1992 Jul; 262(1):238-45. PubMed ID: 1378092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

  • 28. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation.
    Mitsui T; Yokoyama S; Shimizu Y; Katsuura M; Akiba K; Hayasaka K
    Thromb Haemost; 1997 May; 77(5):991-5. PubMed ID: 9184416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S; Westwick J; Kakkar VV
    Biochem Pharmacol; 1984 Oct; 33(19):3025-35. PubMed ID: 6091666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets.
    Habib A; FitzGerald GA; Maclouf J
    J Biol Chem; 1999 Jan; 274(5):2645-51. PubMed ID: 9915793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets.
    Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY
    Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An inhibitor of collagen-induced platelet aggregation from the saliva of Triatoma pallidipennis.
    Noeske-Jungblut C; Krätzschmar J; Haendler B; Alagon A; Possani L; Verhallen P; Donner P; Schleuning WD
    J Biol Chem; 1994 Feb; 269(7):5050-3. PubMed ID: 8106481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
    Krishnamurthi S; Joseph S; Kakkar VV
    Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
    Turini ME; Holub BJ
    Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of leukotriene C4 synthase in human platelets via receptor-mediated mechanisms.
    Edenius C; Tornhamre S; Näsman-Glaser B; Eriksson I; Björkholm S; Lindgren JA
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():333-5. PubMed ID: 7732865
    [No Abstract]   [Full Text] [Related]  

  • 37. Role of thromboxane A2.
    Ambler J; Birch J; Maguire ED; Wallis RB
    Adv Exp Med Biol; 1985; 192():293-308. PubMed ID: 2939695
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
    Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
    J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood.
    Sanderson HM; Heptinstall S; Vickers J; Lösche W
    Blood Coagul Fibrinolysis; 1996 Mar; 7(2):245-8. PubMed ID: 8735830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.